Signal Dx Shifts Focus, Targets Amplification Technology for US Market

Signal Diagnostics' TB test, which is based on the company's DFA technology, was originally directed at third-world countries. But after failing to gain traction, the company is turning to the US and developing new assays to meet market needs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories